MetLife Investment Management’s Praxis Precision Medicines PRAX Stock Holding History

MetLife Investment Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26.1M	Buy	80,930 +68,506	+551%	+$21.2M	0.13%	115
2025 Q4	$3.66M	Buy	12,424 +1,904	+18%	+$355K	0.02%	775
2025 Q3	$558K	Hold	10,520	–	–	﹤0.01%	1757
2025 Q2	$442K	Sell	10,520 -77	-0.7%	-$2.93K	﹤0.01%	1736
2025 Q1	$401K	Sell	10,597 -78	-0.7%	-$4.87K	﹤0.01%	1824
2024 Q4	$822K	Buy	10,675 +544	+5%	+$39.4K	﹤0.01%	1518
2024 Q3	$583K	Buy	10,131 +5,708	+129%	+$308K	﹤0.01%	1699
2024 Q2	$183K	Buy	+4,423	New	+$209K	﹤0.01%	2309
2022 Q2	–	Sell	-1,296	Closed	-$198K	–	2896
2022 Q1	$198K	Buy	1,296 +423	+48%	+$86.9K	﹤0.01%	2358
2021 Q4	$258K	Buy	873 +150	+21%	+$44K	﹤0.01%	1896
2021 Q3	$200K	Hold	723	–	–	﹤0.01%	2101
2021 Q2	$198K	Buy	723 +377	+109%	+$135K	﹤0.01%	2181
2021 Q1	$170K	Hold	346	–	–	﹤0.01%	2139
2020 Q4	$286K	Buy	+346	New	+$202K	﹤0.01%	1792

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

MetLife Investment Management's PRAX Position: Q1 2026 in Review

MetLife Investment Management increased its Praxis Precision Medicines (PRAX) stake by 551% in Q1 2026, buying an estimated $21.2M and bringing the position to 80,930 shares worth $26.1M. The position accounts for 0.13% of the portfolio, ranked #115.

MetLife Investment Management first reported a position in PRAX in Q4 2020 and has held it in 14 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

MetLife Investment Management held 80,930 shares of Praxis Precision Medicines worth $26.1M as of Q1 2026.
MetLife Investment Management bought 68,506 Praxis Precision Medicines shares in Q1 2026, an estimated $21.2M.
Praxis Precision Medicines made up 0.13% of MetLife Investment Management's portfolio in Q1 2026, its #115 holding.
MetLife Investment Management first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 14 quarters since.
289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.